MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening

T Iehara*,1, H Hosoi1, K Akazawa2, Y Matsumoto1, K Yamamoto3, S Suita4, T Tajiri4, T Kusafuka5, E Hiyama6, M Kaneko1, F Sasaki1, T Sugimoto1 and T Sawada1, Committee of Neuroblastoma in the Japanese Society of Pediatric Oncology

1Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji Kamigyo-ku, Kyoto 602-8566, Japan; 2Department of Medical Informatics, Niigata University Medical Hospital, Asahimachi-dori 1-754, Niigata 951-8520, Japan; 3Saitama Children’s Medical Center, Division of Hematology/Oncology, Iwatsuki, Saitama 339-0077, Japan; 4Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan; 5Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan; 6Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 734-8551, Japan; 7Department of Pediatric Surgery, University of Tsukuba, Tsukuba 305-0005, Japan; 8Pediatric Surgery, Hokkaido University School of Medicine, Sapporo 060-8638, Japan

MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three groups (99, 89 and 53%, respectively) were significantly different (P<0.001), indicating that MYCN copy number correlates with the prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs; P<0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin than non-amplified patients (P=0.049, P=0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is indispensable.

British Journal of Cancer (2006) 94, 1510–1515. doi:10.1038/sj.bjc.6603149 www.bjcancer.com
Published online 2 May 2006
© 2006 Cancer Research UK

Keywords: neuroblastoma; infant; MYCN; mass screening

Neuroblastoma (NB) is characterized by heterogeneous tumours, some of which regress spontaneously while others proliferate and progress (D’Angio et al, 1971; Evans et al, 1971; Look et al, 1991). The prognosis for NB in infants is much more favourable than it is in older children. In 1973, the Mass Screening Program for Neuroblastoma (MSPN) was commenced for the early detection of NB in children living in Kyoto, Japan. A nationwide MSPN for 6-month-old infants began in 1985 (Sawada et al, 1984). The latter MSPN revealed incidences of infantile NB in the early stages and good biological prognostic factors of tumours increased (Hachitanda et al, 1994; Sawada et al, 1998). However, it has been argued that MSPN might result in the overdiagnosis of tumours, because some of the tumours might spontaneously regress (Yamamoto et al, 2002; Honjyo et al, 2003). And, the researcher has concluded that the screening was ineffective, because clustered randomized trials have not shown that screening led to a significant reduction in mortality rate from NB (Woods et al, 2002; Kerbl et al, 2003). Consequently, criticism has arisen that MSPN might detect only redundant tumours with good prognostic factors. Actually, the prognosis in most NB cases detected by MSPN has proved to be good. However, some cases detected by MSPN have poor prognostic factors resulting in relapsed disease (Kusafuka et al, 1995). Moreover, there are reports that the good prognosis has been obtained by early treatment in infantile NB cases with poor prognostic factors (Kusafuka et al, 1995; Tanaka et al, 1998).

Although MYCN is well known to be the most powerful prognostic factor in noninfantile cases of NB, how MYCN is related to the prognosis of infantile cases, especially those discovered by MSPN, is not clear. Therefore, we assessed MYCN amplification (MNA) in infantile cases. If the prognoses of infantile NB cases detected by mass screening and MNA correlate strongly, it is necessary to evaluate MNA to decide on the appropriate treatment for these cases.

PATIENTS AND METHODS

Analysis of urine catecholamine

Kits for screening children for urinary catecholamines were provided to the parents at public health centres throughout Japan.
when they brought their child in for a health checkup at 3 months of age. Urine was collected by parents at home and sent to screening centres by mail. Urine samples were assayed for vanillylmandelic acid (VMA) and homovanillic acid (HVA) by high-performance liquid chromatography (HPLC). When children’s urinary levels of either VMA or HVA were > 2.5 s.d. above normal, the child was given clinical examinations for NB at a hospital. The normal range was based on levels in healthy infants of an age-matched (Sawada, 1988).

**Patient population**

Between April 1987 and March 2000, the population of the target infants was 17,139,975. Of this number, 14,496,103 (84.6%) were screened for elevated catecholamine levels. Of this number, 2084 children were diagnosed as having NB based on urinary catecholamine levels and were registered with the Committee of Neuroblastoma in the Japanese Society of Pediatric Oncology.

**Staging** The extent of the disease was evaluated according to the Evans’s stage classification (Evans et al, 1971). The International Staging System (INSS) (Brodeur et al, 1993) had not yet been introduced when the MSPN began.

**Biological features** The prognosis and clinical features of these cases were evaluated on the basis of the MNA. **MYCN** amplification in tumour samples was detected using a Southern blot analysis with **MYCN** second-exon probe according to standard procedures (Brodeur et al, 1984). Although cases with 10 copies or more of the **MYCN** gene are classified into the high-risk group in Japan (Kaneko et al, 2002), in this study the **MYCN** gene was considered amplified if there were more than three copies.

**Registry**

The hospitals reported the cases to the registration centre within 2 years of the findings of elevated catecholamine levels in the screening process. The hospital reported the outcome of each case 5 years after the initial diagnosis of NB. However, the outcome of the cases diagnosed between 1999 and 2000 has been 2 years since the appearance of disease.

**Statistical analysis**

The Kaplan–Meier product limit method was used to estimate the event-free survival (EFS) and overall survival (OS) from the time of diagnosis of NB. The log-rank test was performed to compare the OS probabilities between subgroups of patients. The differences between dichotomous variables were analysed by the χ² test when samples were of sufficient size. The two-tailed t-test was carried out to compare the distributions of continuous variables. A two-tailed P-value of < 0.05 was considered to indicate statistical significance.

**RESULTS**

Of 1533 infants with elevated urinary catecholamine levels that were examined for MNA, 33 (2.2%) had tumours with MNA. Of these 33 cases, 20 had MNA values from three to nine copies of the **MYCN** gene (Table 1). Seventy-seven percent of cases with no MNA had early stage (stages I, II and IVs) tumours. Thirteen cases had more than 10 copies. Of these, only 30% had early stage tumours. The cases without MNA had significantly higher percentage of early stage tumours than cases with MNA over 10 copies (P < 0.001) (Table 2).

**Treatment and survival rates in patients with MNA**

All of the 13 cases with MNA of more than 10 copies received megatherapy with stem cell transplantation and radiotherapy. Six of these cases died. None of 20 cases with MNA from three to nine copies received the megatherapy with stem cell transplantation. Sixteen of the 20 cases received mild chemotherapy, and four cases received only surgical resection without chemotherapy. Only two of the 20 cases died (Table 1). Case 15 had the unresectable tumour of stage III and died of progressive disease although he had received chemotherapy. Case 30 had the resectable tumour with **MYCN** 3 copies by the Southern blot analysis and was not classified into the high-risk group. At 3 months after the operation, this patient had relapse with bone and bone marrow metastasis and died of progressive disease. The primary tumour was judged **MYCN** amplification by the FISH method that was performed after the relapse.

**Outcome**

Of the 2084 cases that were detected NBs by the screening programme, only 15 cases (0.7%) died within 5 years. OS was 99%. Three-year EFS was 99% for cases without MNA (n = 1500), 88% for cases with MNA from three to nine copies (n = 20), and 46% for cases with MNA over 10 copies (n = 13) (P < 0.001) (Figure 1). The 4-year OS rate was 99% for cases without MNA, 89% for cases with MNA from three to nine copies and 53% for cases with MNA over 10 copies (P < 0.001). In the cases with MNA over 10 copies, all of the five cases except one died of progressive disease, though they were received chemotherapy.

**Characteristics of patients with and without MNA**

Table 2 lists the clinical and biological characteristics of patients with and without MNA. The cases with MNA (> 10 copies) were found more frequently in advanced stages (stages III and IV), than the cases without MNA (69 and 23%, respectively; P < 0.001). Of the cases with MNA (> 10 copies), a significantly higher percentage of primary tumours was found in the adrenal glands (92%) than in those without MNA (51%; P = 0.002). The patients with MNA (> 10 copies) had significantly higher serum levels of neuron-specific enolase (NSE) and ferritin than the patients without MNA (P = 0.049, P = 0.025, respectively). Although the patients with MNA (> 10 copies) had significantly higher urinary levels of HVA than the patients without MNA (P = 0.008), there was no difference in urinary levels of HVA (P = 0.985).

**Characteristics of patients with MNA**

The right side of Table 2 shows clinical and biological characteristics of 33 cases with MNA more than three copies. Patients in advanced stages (stage III and IV) had significantly poorer prognoses (3-year EFS; 58.3%) than those in early stages (stage I, II and IVs) (3-year EFS; 93.3%) (P = 0.021). The patients with primary tumours found in the adrenal gland had significantly poorer prognoses (3-year EFS; 68%) than those with the tumours at other sites (3-year EFS; 100%) (P = 0.021). The group with high serum levels of NSE also had a significantly poorer prognosis than the group with low levels of NSE (P = 0.0005). However, urinary levels of VMA and HVA, and serum levels of ferritin, did not correlate with clinical outcomes (P = 0.564, 0.478 and 0.174, respectively).

**DISCUSSION**

It is well known that the prognosis for NB in infants is good. Indeed, the prognosis for NB detected by the Japanese MSPN was excellent, with 98% survival. Although most of the cases detected
by the MSPN had biologically favourable factors, such as no-deletion of lp and low expression of the TRK-A gene, some cases with unfavourable prognostic factors have been reported (Matsunaga et al, 2000; Tajiri et al, 2001). MYCN is one of the most important prognostic factors in NB (Rubie et al, 1997; Tonini et al, 1997). How MYCN is related to the prognosis and clinical features of infantile cases, especially those discovered by MSPN, is not clear. Our large-scale study clarified the frequency and clinical features, including the prognoses, of the infantile NB cases with MNA that were detected by MSPN.

Among 1533 cases discovered by the MSPN, 33 cases (2.2%) showed MNA. This frequency is much lower than the 15–22% frequency of MNA cases reported in the United States and Europe (Tonini et al, 1997; Brodeur, 2003). In addition, in infants that were less than 1-year-old, the frequency of MNA in our study was lower than that reported in Italy (6.8%) (Tonini et al, 1997). This suggests that the MSPN detected a greater number of tumours that spontaneously regressed and/or matured than did the clinical examinations.

MYCN is the powerful prognostic factor in infants whose NB was discovered by the MSPN. The 3-year EFS rates (46%) and 4-year OS rates (53%) for patients with MNA were significantly lower than those for patients without MNA (99.3% and 99%, respectively) (P<0.001). According to our previous investigation, the 4-year OS rate for cases less than 12 months old with MNA of over 10 copies, which include clinically detected cases, was 41% (Ikeda et al, 2002). The prognosis of cases with MNA detected by MSPN might be comparatively good though prognoses cannot be compared because the researches the survival rates of cases detected clinically and cases detected by MSPN did not investigated at the same time.

The infants with MNA that were detected by MSPN might be considered to have benefited from the early detection provided by the screening. Indeed, among patients with MNA, the 3-year EFS rates (93.3%) of patients in stages I, II and IVs were significantly higher than those in stages III and IV (58.3%). If these cases with MNA were not discovered in the early stage by MSPN, some malignant components of tumours would proliferate and progress. As a result, the tumours would be discovered clinically after the patients were 1-year-old. However, the number of cases with MNA is only a very small proportion (2.2%) of the total cases discovered by MSPN. In addition, it is clear that the number of NB patients increased by introduction of MSPN. Therefore, the effectiveness of MSPN discovery of patients with MNA is unclear.

Furthermore, tumours detected by MSPN might regress spontaneously (Yamamoto et al, 1998). Several institutions in Japan recently adopted a conservative approach (the 'wait and see' approach), in which children discovered to have stage I, II or IVs tumours by the MSPN were not given any therapeutic treatment in the expectation that the tumour would spontaneously regress (Yamamoto et al, 1998). However, a careful follow-up is necessary in cases detected by MSPN, because some of the cases were found to have MNA in the early stage. Most cases with MNA in this study did not have higher urinary VMA levels than without MNA and then, they were not predicted to have a poor clinical outcome at their initial onset. Even in the early stages (stages I, II and IVs), biopsies are required in order to determine the biological prognostic factors of the tumour.

Moreover, in this study, it became clear that patients with MNA of three to nine copies also had poor prognoses. MYCN gene has

| Case No. | MYCN | Stage | Surgery | Chemotherapy | Radio therapy | Therapy | Outcome | Follow-up (year) |
|----------|------|-------|---------|--------------|--------------|---------|---------|-----------------|
| 1        | 150  | 3     | CE      | VCR, CPM     | (−)          | NED     | 0.8     |                 |
| 2        | >100 | 4     | B       | VCR, CPM, VP-16, ADR, CDDP, DTI C | (−)          | Auto-BMT | NED     | 0.3†          |
| 3        | 55   | 4     | CE      | CPM, VP-16, THP-ADR, CDDP, L-PAM, CBDCA | (−)          | NED     | 5.5     |                 |
| 4        | 50   | 4     | CE      | (+)         | (+) 25 gy    | PBSCT    | Tumour death | 2.3†          |
| 5        | 50   | 4     | CE      | (+)         | (−)          | PBSCT    | Tumour death | 0.7†          |
| 6        | 29   | 4     | CE      | CPM, VP-16, THP-ADR, CDDP | (−)          | Therapy | 1.0†    |                 |
| 7        | 24   | 2     | CE      | VCR, CPM, VP-16, THP-ADR, CDDP | (+) 20 gy    | NED     | 5.9     |                 |
| 8        | 20   | 2     | CE      | VCR, CPM, VP-16, THP-ADR, CDDP | (+) 20 gy    | NED     | 7.4     |                 |
| 9        | 15   | 4s    | CE      | (+)         | (−)          | Auto-BMT | Tumour death | 5.1           |
| 10       | 14   | 4s    | B       | CPM VP-16, THP-ADR, CDDP | (+) 12 gy    | NED     | 2.5†    |                 |
| 11       | 12   | 4     | CE      | (+)         | (−)          | CBSCT    | NED     | 2.0†          |
| 12       | 10   | 3     | CE      | VCR, CPM, CDDP, VP-16 | (+) 10 gy    | NED     | 3.0     |                 |
| 13       | 10   | 4s    | CE      | CPM, VP-16, THP-ADR, CDDP | (−)          | NED     | 4.7     |                 |
| 14       | 6    | 4s    | CE      | CPM, VP-16, THP-ADR, CDDP | (−)          | NED     | 5.2     |                 |
| 15       | 5.7  | 3     | B       | VCR, CPM, VP-16, THP-ADR, CDDP | (+) 30 gy    | NED     | 5.0     |                 |
| 16       | 5    | 2     | CE      | VCR, CPM   | (+) 24 gy    | NED     | 10.2    |                 |
| 17       | 5    | 2     | CE      | VCR, CPM, ADR, CDDP | (−)          | NED     | 8.1     |                 |
| 18       | 4–5  | 4     | CE      | VCR, CPM, VP-16, THP-ADR, CDDP | (−)          | NED     | 8.8     |                 |
| 19       | 4    | 1     | CE      | VCR, CPM   | (−)          | NED     | 6.6     |                 |
| 20       | 4    | 1     | CE      | VCR, CPM   | (−)          | NED     | 8.7     |                 |
| 21       | 4    | 1     | CE      | VCR, CPM   | (−)          | NED     | 6.1     |                 |
| 22       | 4    | 3     | PE      | CPM, VP-16, ADR, CDDP | (−)          | NED     | 7.5     |                 |
| 23       | 3.7  | 4s    | CE      | VCR, CPM, ADR, CDDP | (−)          | NED     | 6.8     |                 |
| 24       | 3    | 1     | CE      | (−)        | (−)          | NED     | 5.7     |                 |
| 25       | 3    | 1     | CE      | (−)        | (−)          | NED     | 5.0     |                 |
| 26       | 3    | 2     | CE      | VCR, CPM, THP-ADR, CDDP | (−)          | NED     | 4.5     |                 |
| 27       | 3    | 2     | CE      | (−)        | (−)          | NED     | 6.0     |                 |
| 28       | 3    | 3     | B       | CPM, VP-16, THP-ADR, CDDP | (−)          | Auto-BMT | NED     | 5.1           |
| 29       | 3    | 3     | CE      | VCR, CPM, VP-16, THP-ADR, CDDP | (−)          | NED     | 2.1     |                 |
| 30       | 3    | 3     | CE      | (+)         | (−)          | NED     | 8.7     |                 |
| 31       | 3    | 4     | CE      | CPM, THP-ADR, CDDP | (−)          | NED     | 7.8     |                 |
| 32       | 3    | 4s    | CE      | (+)         | (−)          | NED     | 9.7     |                 |
| 33       | 2–4  | 4     | B       | VCR, CPM, THP-ADR, CDDP | (−)          | NED     | 9.7     |                 |
2006 Cancer Research UK

Table 2 Characteristics of patients with and without MYCN amplification detected by mass screening for neuroblastoma

| Number of cases (%) | MNA (10) | MNA (9-3) | MNA (0) | P-value | MNA (+, >3) 3-yr EFS | P-value |
|---------------------|----------|-----------|---------|---------|-----------------------|---------|
| Patient characteristics | (n = 13) | (n = 20) | (n = 1500) |         |                       |         |
| Tumour stage        |          |          |         |         |                       |         |
| I                   | 0 (0)    | 5 (25)   | 595 (40) | P < 0.001* | 100                    | P = 0.021 |
| II                  | 2 (15)   | 5 (25)   | 463 (31) | (1.24, 3.4) | 86                    | (1.24, 3.4) |
| III                 | 2 (15)   | 5 (25)   | 280 (19) | 71       |                       |         |
| IV                  | 7 (54)   | 2 (10)   | 65 (4)   | 44       |                       |         |
| Nv                  | 2 (15)   | 3 (15)   | 97 (6)   | 100      |                       |         |
| Gender              |          |          |         |         |                       |         |
| Female              | 3 (23)   | 11 (55)  | 722 (49) | P = 0.043* | 86                    |         |
| Male                | 11 (77)  | 9 (45)   | 764 (51) | 68       |                       |         |
| Primary site        |          |          |         |         |                       |         |
| Adrenal gland       | 12 (92)  | 13 (65)  | 764 (51) | P = 0.002* | 68                    | P = 0.021 |
| Other abdominal     | 0 (0)    | 3 (15)   | 456 (30) | (adrenal gland/other site) | 100      | (adrenal gland/other site) |
| Chest               | 1 (8)    | 3 (15)   | 224 (15) | 100      |                       |         |
| Pelvis              | 0 (0)    | 1 (5)    | 50 (3)   | 100      |                       |         |
| Neck                | 0 (0)    | 0 (0)    | 6 (0)    | 100      |                       |         |
| VMA                 |          |          |         |         |                       |         |
| <20 μg mgCr⁻¹       | 3 (23)   | 4 (20)   | 293 (20) | 100      |                       |         |
| 21 – 100 μg mgCr⁻¹  | 7 (54)   | 15 (75)  | 982 (67) | 82       |                       |         |
| >101 μg mgCr⁻¹      | 2 (15)   | 1 (5)    | 184 (13) | 75       |                       |         |
| (mean: 74.6 μg mgCr⁻¹) |         | (mean: 54.8 μg mgCr⁻¹) | (mean: 54.4 μg mgCr⁻¹) |         |                       |         |
| P = 0.985⁰, P = 0.977³ | P = 0.364 |          |         |         |                       |         |
| HVA                 |          |          |         |         |                       |         |
| <20 μg mgCr⁻¹       | 0 (0)    | 2 (10)   | 206 (14) | 100      |                       |         |
| 21 – 100 μg mgCr⁻¹  | 7 (54)   | 16 (80)  | 1084 (74) | 78       |                       |         |
| >101 μg mgCr⁻¹      | 6 (46)   | 2 (10)   | 170 (12) | 63       |                       |         |
| (mean: 107.1 μg mgCr⁻¹) | (mean: 66.0 μg mgCr⁻¹) | (mean: 55.6 μg mgCr⁻¹) |         |         |                       |         |
| P = 0.008⁰, P = 0.371³ | P = 0.478 |          |         |         |                       |         |
| NSE                 |          |          |         |         |                       |         |
| <15 ng ml⁻¹         | 5 (38)   | 9 (45)   | 526 (47) | 93       |                       |         |
| 16 – 100 ng ml⁻¹    | 2 (15)   | 7 (35)   | 568 (51) | 89       |                       |         |
| >101 ng ml⁻¹        | 6 (46)   | 2 (10)   | 14 (1)   | 25       |                       |         |
| (mean: 266.9 ng ml⁻¹) | (mean: 32.6 ng ml⁻¹) | (mean: 26.2 ng ml⁻¹) | P = 0.049⁰, P = 0.285³ | P = 0.0005 |         |         |
| Fenitin             |          |          |         |         |                       |         |
| <30 ng ml⁻¹         | 2 (15)   | 5 (25)   | 506 (54) | 100      |                       |         |
| 31 – 100 ng ml⁻¹    | 5 (38)   | 8 (40)   | 383 (41) | 69       |                       |         |
| >101 ng ml⁻¹        | 6 (46)   | 1 (5)    | 54 (6)   | 43       |                       |         |
| (mean: 167.3 ng ml⁻¹) | (mean: 55.9 ng ml⁻¹) | (mean: 33.7 ng ml⁻¹) | P = 0.025⁰, P = 0.032³ | P = 0.174 |         |         |

*P-value between MNA (10) and MNA (0). ³P-value between MNA (9-3) and MNA (0).

been analysed by the Southern blotting method for whole tumours, but this method is not able to evaluate the status MNA in individual NB cells. While, the FISH method is able to evaluate MNA individual tumour cells, however, it is difficult to determine the copy number of MNA by the FISH method. MYCN amplification was defined as a more than fourfold increase of MYCN signals in relation to the number of chromosomes 2 in FISH method. Moreover, additional copies up to the fourfold were defined as MYCN gain (Spitz et al., 2004). Spitz reported that 6% of tumours displayed MYCN gain and this MYCN gain was associated only with a poor outcome in localized or 4s NB cases (Spitz et al., 2004). In our study, these patients with MNA of three to nine copies might suggest the MYCN gain rather than MYCN amplification. In cases 4 and 30, MNA were confirmed by FISH method, however, in all the cases MNA were not confirmed by it. MYCN amplification must be determined by adding the FISH method in these cases (Mathew et al., 2001).

In the studies of the USA group (COG) and the German group, the therapeutic strategy of surgical resection or observation is recommended for NB patients in stages I or II, regardless of the presence of MNA (Cohn et al., 1995; Kawa et al., 1999; Berthold and Hero, 2000; Perez et al., 2000). However, in Japan, patients with MNA of more than 10 copies are classified as being in a high-risk group. In the protocol for high-risk NB, patients receive intensive chemotherapy combined with stem cell transplantation (Kawa et al., 1999; Kaneko et al., 2002). Infantile NB patients with MNA as well as patients in the high-risk group more than 1-year-old with MNA of over 10 copies have been receiving intensive chemotherapy (Matsumura and Michon, 2000). In our study 29 of 33 cases with MNA received chemotherapy regardless of the stage. The use of chemotherapy might improve the prognosis of patients with MNA. In the cases with MNA over 10 copies, the treatment strategy including more intensive chemotherapy might be necessary, because five cases except one died of progressive disease. For cases with
MNA, it is necessary to establish and perform the appropriate treatment, including not only surgical resection but also chemotherapy. MYCN amplification was strongly and inversely correlated with the prognosis in infantile cases, although the frequency of MNA in the cases discovered through the MSPN was small (2.2%). Prediction of the presence of MNA in the tumor based on urinary levels of HVA and VMA and stage of the tumor was difficult in the cases we encountered. Our results demonstrate that evaluation of MNA is important for the selection of appropriate treatment for infantile NB.

REFERENCES

Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59: 1261 – 1277

Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203 – 216

Brodeur GM, Pritchrd J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466 – 1477

Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121 – 1124

Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H (1995) Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study. Cancer Res 55: 721 – 726

D’angio GJ, Evans AE, Koop CE (1971) Special pattern of widespread neuroblastoma with a favorable prognosis. Lancet 1: 1046 – 1049

Evans AE, D’angio GJ, Randolph J (1971) A proposal staging for children with neuroblastoma. Cancer 27: 374 – 378

Hachitanda Y, Ishimoto K, Hata J, Shimada H (1994) One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 74: 3223 – 3226

Honjyo S, Doran H, Stiler C, Aiki W, Tsukuma H, Oshima A, Coleman MP (2003) Neuroblastoma trends in Osaka, Japan, and Great Britain 1970 – 1994, in relation to screening. Int J Cancer 103: 538 – 543

Ikeda H, Iehara T, Tsuchida Y, Kaneko M, Hata J, Naito H, Iwafuchi M, Ohnuma N, Mugishima H, Ohshima M, Hamazaki M, Mimaya J, Kondo S, Kawamura K, Okada A, Hiyama E, Hata J, Shimada H (2002) Experience with International Neuroblastoma Staging System and Pathology Classification. Br J Cancer 86: 1110 – 1116

Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawamura K, Iwafuchi M, Sawada T, Suita S (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24: 613 – 621

Kawa K, Ohnuma N, Kaneko M, Yamamoto K, Etoh T, Mugishima H, Ohhira M, Yokoyama J, Bessho F, Honna T, Yoshizawa J, Nakada K, Iwafuchi M, Nozaki T, Mimaya J, Sawada T, Nakamura T, Miyata H, Yamato K, Tsuchida Y (1999) Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 17: 3216 – 3220

Kerbl R, Urban CE, Ambros IM, Dornbusch HJ, Schwinger W, Lackner H, Ladenstein R, Strenger V, Gadner H, Ambros PF (2003) Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol 21: 4228 – 4234

Kusafuka T, Nagahara N, Oue T, Imura K, Nakamura T, Kobayashi Y, Komoto Y, Fukuwazuma M, Okada A, Nakayama M (1995) Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening. Cancer 76: 695 – 699

Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol 9: 581 – 591

Mathew P, Valentine MB, Bowman LC, Rowe ST, Nash MB, Valentine VA, Cohn SL, Castleberry RP, Brodeur GM, Look AT (2001) Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 3: 105 – 109

Matsunaga T, Shirasawa H, Hishiki T, Yoshida H, Kouchi K, Ohtsu Y, Kawamura K, Etoh T, Ohnuma N (2000) Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening. Clin Cancer Res 6: 3199 – 3204

ACKNOWLEDGEMENTS

The authors gratefully thank many pediatric oncologists and pediatric surgeons in Japan for providing us the important clinical data of patients study. This study was supported in part by grants for cancer and mass-screening research from the Kyoto Prefectural Government and the Children’s Cancer Association of Japan. This study was also supported in part by Grant-in-Aid for Scientific Research (16-Kodomo-012) from the Ministry of Health, Labour, and Welfare of the Government of Japan.
Perez CA, Matthy KK, Atkinsin JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN (2000) Biologic variable in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. *J Clin Oncol* 18: 18 – 26

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Benard J, Delattre O, Favrot M, Peyroulot MC, Thyss A, Perel Y, Bergeron C, Bourbon-Collet B, Vannier JP, Lemerle J, Sommelet D (1997) *N*-myc gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 study. *J Clin Oncol* 15: 1171 – 1182

Sawada T (1988) Laboratory techniques and neuroblastoma screening. *Lancet* 2: 1134 – 1135

Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, Mori T, Maeda K, Koide R, Hanawa Y, Tsunoda A (1984) Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening group. *Lancet* 2: 271 – 273

Sawada T, Nishi M, Takeda T, Iehara T (1998) Mass screening for neuroblastoma in Japan. *Med Pediatr Oncol* 31: 429 – 434

Spitz R, Hero B, Skowron M, Ernestus K, Berthold F (2004) *MYCN*-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. *Eur J Cancer* 40: 2753 – 2759

Tajiri T, Suita S, Sera Y, Takamatsu H, Mizote H, Nagasaki A, Kurosaki N, Handa N, Hara T, Okamura J, Miyazaki S, Sugimoto T, Kawakami K, Eguchi H, Tsuneyoshi M (2001) Clinical and Biologic Characteristics for recurring neuroblastoma at mass screening cases in Japan. *Cancer* 92: 349 – 353

Tanaka T, Sugimoto T, Sawada T (1998) Prognostic discrimination among neuroblastomas according to *Ha-ras/trk A* gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening. *Cancer* 83: 1626 – 1633

Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B (1997) *MYCN* oncogene amplification in neuroblastoma is associated with prognosis, except in stage 4s: The Italian experience with 295 children. *J Clin Oncol* 15: 85 – 93

Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, Bunin G, Levy I, Brossard J, Dougherty G, Tuchman M, Lemieux B (2002) Screening of infants and mortality due to neuroblastoma. *N Engl J Med* 346: 1041 – 1046

Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E, Moritani T, Shimano Y, Tanimura M, Hayashi Y (1998) Spontaneous regression of localized neuroblastoma detected by mass screening. *J Clin Oncol* 16: 1265 – 1269

Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, Higashigawa M, Tanimura M (2002) Marginal decrease in mortality and marked increase in incidence as result of neuroblastoma screening at 6 months of age: Cohort study in seven prefectures in Japan. *J Clin Oncol* 20: 1209 – 1214

**Appendix A1**

**Participating institutions main investigators**

Gunma Children’s Medical Center, Gunma (Tsuchida Y, Kuroiwa M); Osaka University, Osaka (Fukuzawa M, Kusafuka T, Yoneda M); Osaka Medical Center for Maternal and Child Health, Osaka (Kawa K, Inoue M, Oue T); Kumamoto University, Kumamoto (Sera Y, Inomata Y); Tokushima University, Tokushima (Takahara H); Hyogo Children’s Hospital, Hyogo (Misu H); Kyushu University, Fukuoka (Suita S, Tajiri T); Keio University, Tokyo (Yokoyama J, Morikawa Y); National Sapporo Hospital, Hokkaido (Hatae Y, Naio H); National Center for Child Health and Development (Honna T); National Nagoya Hospital, Aichi (Horibe K); Tohoku University, Miyagi (Hayashi Y); Nihon University, Tokyo (Mugishima H, Koshinaga T); Dokkyo University, Saitama (Ikeda H).